{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T21:35:38Z","timestamp":1792186538963,"version":"4.4.0"},"reference-count":117,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81673647"],"award-info":[{"award-number":["81673647"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82074069"],"award-info":[{"award-number":["82074069"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.ejmech.2021.113690","type":"journal-article","created":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T11:42:11Z","timestamp":1625485331000},"page":"113690","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":159,"special_numbering":"C","title":["Treatment for liver cancer: From sorafenib to natural products"],"prefix":"10.1016","volume":"224","author":[{"given":"Shuli","family":"Man","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganggang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyuan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2021.113690_bib1","first-page":"7","article-title":"Cancer statistics","volume":"69","author":"Siegel","year":"2019","journal-title":"CA A Cancer J. Clin."},{"key":"10.1016\/j.ejmech.2021.113690_bib2","doi-asserted-by":"crossref","first-page":"452","DOI":"10.21037\/hbsn-20-480","article-title":"Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights","volume":"9","author":"Xie","year":"2019","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"10.1016\/j.ejmech.2021.113690_bib3","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13045-019-0794-6","article-title":"Emerging agents and regimens for hepatocellular carcinoma","volume":"12","author":"Zhu","year":"2019","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2021.113690_bib4","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1021\/acs.jnatprod.5b01055","article-title":"Natural products as sources of new drugs from 1981 to 2014","volume":"79","author":"Newman","year":"2016","journal-title":"J.\u00a0Nat. Prod."},{"key":"10.1016\/j.ejmech.2021.113690_bib5","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1002\/ptr.4609","article-title":"Anticancer drugs from traditional toxic Chinese medicines","volume":"26","author":"Man","year":"2012","journal-title":"Phytother Res. : PTR"},{"key":"10.1016\/j.ejmech.2021.113690_bib6","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.fitote.2010.06.004","article-title":"Chemical study and medical application of saponins as anti-cancer agents","volume":"81","author":"Man","year":"2010","journal-title":"Fitoterapia"},{"key":"10.1016\/j.ejmech.2021.113690_bib7","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1055\/s-0040-1708876","article-title":"Hepatic stellate cell-macrophage crosstalk in liver fibrosis and carcinogenesis","volume":"40","author":"Matsuda","year":"2020","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.ejmech.2021.113690_bib8","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.jhep.2015.04.021","article-title":"I.\u00a0Chronic Hepatitis Cohort Study, Increased incidence of cancer and cancer-related mortality among persons with chronic hepatitis C infection, 2006-2010","volume":"63","author":"Allison","year":"2015","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.ejmech.2021.113690_bib9","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1002\/ijc.30161","article-title":"Tobacco carcinogen induces both lung cancer and non-alcoholic steatohepatitis and hepatocellular carcinomas in ferrets which can be attenuated by lycopene supplementation, International journal of cancer","volume":"139","author":"Aizawa","year":"2016","journal-title":"J.\u00a0Int. Cancer"},{"key":"10.1016\/j.ejmech.2021.113690_bib10","doi-asserted-by":"crossref","DOI":"10.1111\/liv.13877","article-title":"Metabolic disorders across hepatocellular carcinoma in Italy","author":"Morisco","year":"2018","journal-title":"Liver Int."},{"key":"10.1016\/j.ejmech.2021.113690_bib11","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1146\/annurev-med-090514-013832","article-title":"Liver cancer: connections with obesity, fatty liver, and cirrhosis","volume":"67","author":"Marengo","year":"2016","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.ejmech.2021.113690_bib12","doi-asserted-by":"crossref","first-page":"e3138","DOI":"10.1038\/cddis.2017.512","article-title":"Phosphoprotein enriched in diabetes (PED\/PEA15) promotes migration in hepatocellular carcinoma and confers resistance to sorafenib","volume":"8","author":"Quintavalle","year":"2017","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejmech.2021.113690_bib13","first-page":"411","article-title":"From NASH to HCC: current concepts and future challenges","volume":"16","author":"Anstee","year":"2019","journal-title":"Nat. Rev."},{"key":"10.1016\/j.ejmech.2021.113690_bib14","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2021.113690_bib15","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1159\/000327558","article-title":"Molecular targeted therapy for hepatocellular carcinoma: bench to bedside","volume":"29","author":"Kudo","year":"2011","journal-title":"Dig. Dis."},{"key":"10.1016\/j.ejmech.2021.113690_bib16","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41586-019-1112-8","article-title":"p38gamma is essential for cell cycle progression and liver tumorigenesis","volume":"568","author":"Tomas-Loba","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2021.113690_bib17","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.jhep.2019.12.006","article-title":"BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA","volume":"72","author":"Hirsch","year":"2020","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.ejmech.2021.113690_bib18","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1055\/s-0030-1247131","article-title":"Molecular classification and novel targets in hepatocellular carcinoma: recent advancements","volume":"30","author":"Hoshida","year":"2010","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.ejmech.2021.113690_bib19","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.4254\/wjh.v7.i15.1964","article-title":"Mechanisms of hepatocellular carcinoma and challenges and opportunities for molecular targeted therapy","volume":"7","author":"Chen","year":"2015","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.ejmech.2021.113690_bib20","first-page":"8","article-title":"NLRP12 suppresses hepatocellular carcinoma via downregulation of cJun N-terminal kinase activation in the hepatocyte","author":"Udden","year":"2019","journal-title":"eLife"},{"key":"10.1016\/j.ejmech.2021.113690_bib21","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/hepr.12795","article-title":"Promising new strategies for hepatocellular carcinoma","volume":"47","author":"Nakamoto","year":"2017","journal-title":"Hepatol. Res. : Off. J. Jpn Soc. Hepatol."},{"key":"10.1016\/j.ejmech.2021.113690_bib22","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.gendis.2020.03.010","article-title":"Targeting angiogenesis for liver cancer: past, present, and future","volume":"7","author":"Zhu","year":"2020","journal-title":"Genes Dis"},{"key":"10.1016\/j.ejmech.2021.113690_bib23","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1159\/000496439","article-title":"Systemic treatment for advanced hepatocellular carcinoma","volume":"8","author":"Bouattour","year":"2019","journal-title":"Liver Canc."},{"key":"10.1016\/j.ejmech.2021.113690_bib24","doi-asserted-by":"crossref","first-page":"783","DOI":"10.2174\/1389450117666151209120831","article-title":"Biology, epidemiology, clinical aspects of hepatocellular carcinoma and the role of sorafenib","volume":"17","author":"Mazzoccoli","year":"2016","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.ejmech.2021.113690_bib25","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.biopha.2017.01.107","article-title":"Sorafenib: a potential therapeutic drug for hepatic fibrosis and its outcomes","volume":"88","author":"Ma","year":"2017","journal-title":"Biomed. Pharmacother= Biomedecine & pharmacotherapie"},{"key":"10.1016\/j.ejmech.2021.113690_bib26","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.canlet.2012.10.021","article-title":"Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth","volume":"329","author":"van Malenstein","year":"2013","journal-title":"Canc. Lett."},{"key":"10.1016\/j.ejmech.2021.113690_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20061292","article-title":"Hexokinase-II inhibition synergistically augments the anti-tumor efficacy of sorafenib in hepatocellular carcinoma","volume":"20","author":"Yoo","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2021.113690_bib28","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.canlet.2018.11.004","article-title":"Androgen receptor (AR)\/miR-520f-3p\/SOX9 signaling is involved in altering hepatocellular carcinoma (HCC) cell sensitivity to the Sorafenib therapy under hypoxia via increasing cancer stem cells phenotype","volume":"444","author":"Xiao","year":"2019","journal-title":"Canc. Lett."},{"key":"10.1016\/j.ejmech.2021.113690_bib29","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1136\/gutjnl-2018-317440","article-title":"Oncofetal HLF transactivates c-Jun to promote hepatocellular carcinoma development and sorafenib resistance","volume":"68","author":"Xiang","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.ejmech.2021.113690_bib30","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/s41416-018-0373-6","article-title":"Integrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinoma","volume":"120","author":"Pinato","year":"2019","journal-title":"Br. J. Canc."},{"key":"10.1016\/j.ejmech.2021.113690_bib31","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.canlet.2019.06.016","article-title":"HIF-1alpha-induced RIT1 promotes liver cancer growth and metastasis and its deficiency increases sensitivity to sorafenib","volume":"460","author":"Song","year":"2019","journal-title":"Canc. Lett."},{"key":"10.1016\/j.ejmech.2021.113690_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2019.01.028","article-title":"Randomized trials and endpoints in advanced HCC: role of PFS as a surrogate of survival","author":"Llovet","year":"2019","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.ejmech.2021.113690_bib33","first-page":"11","article-title":"Current status of gene therapy in hepatocellular carcinoma","author":"Reghupaty","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2021.113690_bib34","doi-asserted-by":"crossref","first-page":"5768","DOI":"10.1158\/1078-0432.CCR-14-0725","article-title":"STAT3 mediates regorafenib-induced apoptosis in hepatocellular carcinoma","volume":"20","author":"Tai","year":"2014","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.ejmech.2021.113690_bib35","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2021.113690_bib36","first-page":"261","article-title":"The advances of traditional Chinese medicine in the treatment of liver diseases in 2019","volume":"5","author":"Cao","year":"2020","journal-title":"Tradit. Chin. Med."},{"key":"10.1016\/j.ejmech.2021.113690_bib37","doi-asserted-by":"crossref","first-page":"109124","DOI":"10.1016\/j.cbi.2020.109124","article-title":"Molecular and cellular basis of the anticancer activity of the prenylated flavonoid icaritin in hepatocellular carcinoma","volume":"325","author":"Bailly","year":"2020","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.ejmech.2021.113690_bib38","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12885-019-5471-1","article-title":"First-in-class immune-modulating small molecule Icaritin in advanced hepatocellular carcinoma: preliminary results of safety, durable survival and immune biomarkers","volume":"19","author":"Fan","year":"2019","journal-title":"BMC Canc."},{"key":"10.1016\/j.ejmech.2021.113690_bib39","series-title":"Icaritin-induced Immunomodulatory Efficacy in Advanced Hepatitis B Virus-Related Hepatocellular Carcinoma: Immunodynamic Biomarkers and Overall Survival","author":"Qin","year":"2020"},{"key":"10.1016\/j.ejmech.2021.113690_bib40","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1158\/1940-6207.CAPR-11-0148","article-title":"Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases--safety, pharmacokinetics, and pharmacodynamics","volume":"4","author":"Howells","year":"2011","journal-title":"Canc. Prev. Res."},{"key":"10.1016\/j.ejmech.2021.113690_bib41","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.3892\/or.2017.5347","article-title":"Resveratrol suppresses human hepatocellular carcinoma via targeting HGF-c-Met signaling pathway","volume":"37","author":"Gao","year":"2017","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ejmech.2021.113690_bib42","doi-asserted-by":"crossref","first-page":"105667","DOI":"10.1016\/j.biocel.2019.105667","article-title":"Resveratrol alleviates non-alcoholic fatty liver disease through epigenetic modification of the Nrf2 signaling pathway","volume":"119","author":"Hosseini","year":"2020","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.ejmech.2021.113690_bib43","doi-asserted-by":"crossref","first-page":"111675","DOI":"10.1016\/j.ejmech.2019.111675","article-title":"Review about the multi-target profile of resveratrol and its implication in the SGK1 inhibition","volume":"183","author":"Catalogna","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113690_bib44","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.nutres.2014.09.005","article-title":"Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease","volume":"34","author":"Faghihzadeh","year":"2014","journal-title":"Nutr. Res. (New York, N.Y"},{"key":"10.1016\/j.ejmech.2021.113690_bib45","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1177\/1534735413490798","article-title":"A\u00a0phase I dose-finding study of silybin phosphatidylcholine (milk thistle) in patients with advanced hepatocellular carcinoma","volume":"13","author":"Siegel","year":"2014","journal-title":"Integr. Canc. Ther."},{"key":"10.1016\/j.ejmech.2021.113690_bib46","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.ctrv.2015.04.008","article-title":"Silibinin and STAT3: a natural way of targeting transcription factors for cancer therapy","volume":"41","author":"Bosch-Barrera","year":"2015","journal-title":"Canc. Treat Rev."},{"key":"10.1016\/j.ejmech.2021.113690_bib47","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/j.freeradbiomed.2012.02.008","article-title":"Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trial","volume":"52","author":"Loguercio","year":"2012","journal-title":"Free Radical Biol. Med."},{"key":"10.1016\/j.ejmech.2021.113690_bib48","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.biopha.2017.11.006","article-title":"Synergistic anticancer activity of 20(S)-Ginsenoside Rg3 and Sorafenib in hepatocellular carcinoma by modulating PTEN\/Akt signaling pathway","volume":"97","author":"Lu","year":"2018","journal-title":"Biomed. Pharmacother= Biomedecine & pharmacotherapie"},{"key":"10.1016\/j.ejmech.2021.113690_bib49","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1148\/radiol.2016150719","article-title":"Prospective study of transcatheter arterial chemoembolization (TACE) with ginsenoside Rg3 versus TACE alone for the treatment of patients with advanced hepatocellular carcinoma","volume":"280","author":"Zhou","year":"2016","journal-title":"Radiology"},{"key":"10.1016\/j.ejmech.2021.113690_bib50","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1021\/acs.molpharmaceut.5b00677","article-title":"Glycyrrhetinic acid mediated drug delivery carriers for hepatocellular carcinoma therapy","volume":"13","author":"Cai","year":"2016","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejmech.2021.113690_bib51","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1038\/ctg.2017.29","article-title":"A\u00a0randomized controlled trial of glycyrrhizin plus tenofovir vs. Tenofovir in chronic hepatitis B with severe acute exacerbation","volume":"8","author":"Hung","year":"2017","journal-title":"Clin. Transl. Gastroenterol."},{"key":"10.1016\/j.ejmech.2021.113690_bib52","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1016\/S0002-9270(01)02612-0","article-title":"Glycyrrhizin-induced reduction of ALT in European patients with chronic hepatitis C","volume":"96","author":"van Rossum","year":"2001","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.ejmech.2021.113690_bib53","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jhep.2006.05.015","article-title":"Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: a randomized phase II trial","volume":"45","author":"Orlent","year":"2006","journal-title":"J.\u00a0Hepatol."},{"issue":"Suppl 2","key":"10.1016\/j.ejmech.2021.113690_bib54","first-page":"S287","article-title":"Glycyrrhizin injection therapy prevents hepatocellular carcinogenesis in patients with interferon-resistant active chronic hepatitis C","volume":"37","author":"Ikeda","year":"2007","journal-title":"Hepatol. Res. : Off. J. Jpn Soc. Hepatol."},{"key":"10.1016\/j.ejmech.2021.113690_bib55","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10620-006-3177-0","article-title":"A\u00a0long-term glycyrrhizin injection therapy reduces hepatocellular carcinogenesis rate in patients with interferon-resistant active chronic hepatitis C: a cohort study of 1249 patients","volume":"51","author":"Ikeda","year":"2006","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.ejmech.2021.113690_bib56","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1365-2893.2011.01579.x","article-title":"Glycyrrhizin in patients who failed previous interferon alpha-based therapies: biochemical and histological effects after 52 weeks","volume":"19","author":"Manns","year":"2012","journal-title":"J.\u00a0Viral Hepat."},{"key":"10.1016\/j.ejmech.2021.113690_bib57","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/nm1135","article-title":"Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins","volume":"10","author":"Kong","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2021.113690_bib58","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.freeradbiomed.2019.06.019","article-title":"Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway","volume":"141","author":"Zhu","year":"2019","journal-title":"Free Radical Biol. Med."},{"key":"10.1016\/j.ejmech.2021.113690_bib59","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0134172","article-title":"Efficacy of berberine in patients with non-alcoholic fatty liver disease","volume":"10","author":"Yan","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.ejmech.2021.113690_bib60","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1186\/s12885-019-5862-3","article-title":"Selective TACE with irinotecan-loaded 40 mum microspheres and FOLFIRI for colorectal liver metastases: phase I dose escalation pharmacokinetic study","volume":"19","author":"Tanaka","year":"2019","journal-title":"BMC Canc."},{"key":"10.1016\/j.ejmech.2021.113690_bib61","doi-asserted-by":"crossref","first-page":"104398","DOI":"10.1016\/j.phrs.2019.104398","article-title":"Irinotecan: 25 years of cancer treatment","volume":"148","author":"Bailly","year":"2019","journal-title":"Pharmacol. Res. : Off. J. Italian Pharmacol. Soc."},{"key":"10.1016\/j.ejmech.2021.113690_bib62","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.jvir.2018.08.010","article-title":"Irinotecan-eluting 75-150-mum embolics lobar chemoembolization in patients with colorectal cancer liver metastases: a prospective single-center phase I study","volume":"29","author":"Fereydooni","year":"2018","journal-title":"J.\u00a0Vasc. Intervent. Radiol. : J. Vasc. Intervent. Radiol."},{"key":"10.1016\/j.ejmech.2021.113690_bib63","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1016\/j.ejso.2016.07.142","article-title":"PARAGON II - a single arm multicentre phase II study of neoadjuvant therapy using irinotecan bead in patients with resectable liver metastases from colorectal cancer","volume":"42","author":"Jones","year":"2016","journal-title":"Eur. J. Surg. Oncol. : J. Eur. Soc. Surg. Oncol. Br. Assoc. Surg. Oncol."},{"key":"10.1016\/j.ejmech.2021.113690_bib64","series-title":"The CIREL Cohort: A Prospective Controlled Registry Studying the Real-Life Use of Irinotecan-Loaded Chemoembolisation in Colorectal Cancer Liver Metastases: Interim Analysis, Cardiovascular and Interventional Radiology","author":"Pereira","year":"2020"},{"key":"10.1016\/j.ejmech.2021.113690_bib65","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/s41416-020-0917-4","article-title":"Intra-arterial hepatic beads loaded with irinotecan (DEBIRI) with mFOLFOX6 in unresectable liver metastases from colorectal cancer: a Phase 2 study","volume":"123","author":"Pernot","year":"2020","journal-title":"Br. J. Canc."},{"key":"10.1016\/j.ejmech.2021.113690_bib66","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1159\/000348579","article-title":"Hepatic arterial infusion with irinotecan in patients with liver metastases of colorectal cancer: results of an extended phase I study","volume":"59","author":"Eichler","year":"2013","journal-title":"Chemotherapy"},{"key":"10.1016\/j.ejmech.2021.113690_bib67","first-page":"1015","article-title":"A\u00a0phase I study of continuous hepatic arterial infusion of Irinotecan in patients with locally advanced hepatocellular carcinoma, Digestive and liver disease","volume":"43","author":"Brandi","year":"2011","journal-title":"Off. J. Italian Soc. Gastroenterol. Italian Assoc. Stud. Liver"},{"key":"10.1016\/j.ejmech.2021.113690_bib68","first-page":"185","article-title":"Phase II study of sequential irinotecan and flavopiridol in patients with advanced hepatocellular carcinoma","volume":"5","author":"Ang","year":"2012","journal-title":"Gastrointest. Canc. Res. : GCR"},{"key":"10.1016\/j.ejmech.2021.113690_bib69","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3109\/08880018.2014.909913","article-title":"Vincristine and irinotecan in children with relapsed hepatoblastoma: a single-institution experience","volume":"32","author":"Zhang","year":"2015","journal-title":"Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2021.113690_bib70","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1016\/j.ejca.2012.06.023","article-title":"Efficacy of irinotecan single drug treatment in children with refractory or recurrent hepatoblastoma--a phase II trial of the childhood liver tumour strategy group (SIOPEL)","volume":"48","author":"Zsiros","year":"2012","journal-title":"Eur. J. Canc."},{"key":"10.1016\/j.ejmech.2021.113690_bib71","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1002\/cncr.29456","article-title":"Randomized clinical control study of locoregional therapy combined with arsenic trioxide for the treatment of hepatocellular carcinoma","volume":"121","author":"Wang","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.ejmech.2021.113690_bib72","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/s41419-019-1676-0","article-title":"Arsenic trioxide inhibits liver cancer stem cells and metastasis by targeting SRF\/MCM7 complex","volume":"10","author":"Wang","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejmech.2021.113690_bib73","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/jgh.13529","article-title":"Arsenic trioxide intravenous infusion combined with transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with pulmonary metastasis: long-term outcome analysis","volume":"32","author":"Hu","year":"2017","journal-title":"J.\u00a0Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejmech.2021.113690_bib74","doi-asserted-by":"crossref","first-page":"31927","DOI":"10.18632\/oncotarget.5578","article-title":"A\u00a0novel anti-cancer agent Icaritin suppresses hepatocellular carcinoma initiation and malignant growth through the IL-6\/Jak2\/Stat3 pathway","volume":"6","author":"Zhao","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2021.113690_bib75","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3389\/fphar.2016.00191","article-title":"Anti-cancer properties of the naturally occurring aphrodisiacs: icariin and its derivatives","volume":"7","author":"Tan","year":"2016","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2021.113690_bib76","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejmech.2015.06.006","article-title":"Synthesis and cancer cell growth inhibitory activity of icaritin derivatives","volume":"100","author":"Wang","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113690_bib77","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.jhep.2012.12.012","article-title":"Resveratrol improves intrahepatic endothelial dysfunction and reduces hepatic fibrosis and portal pressure in cirrhotic rats","volume":"58","author":"Di Pascoli","year":"2013","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.ejmech.2021.113690_bib78","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1002\/mnfr.201500016","article-title":"Resveratrol improves hepatic steatosis by inducing autophagy through the cAMP signaling pathway","volume":"59","author":"Zhang","year":"2015","journal-title":"Mol. Nutr. Food Res."},{"key":"10.1016\/j.ejmech.2021.113690_bib79","first-page":"4631","article-title":"Metabolic profile and structure-activity relationship of resveratrol and its analogs in human bladder cancer cells","volume":"11","author":"Yang","year":"2019","journal-title":"Canc. Manag. Res."},{"key":"10.1016\/j.ejmech.2021.113690_bib80","first-page":"450","article-title":"Structure-activity relationship of trans-resveratrol and its analogues","volume":"52","author":"Ovesna","year":"2005","journal-title":"Neoplasma"},{"key":"10.1016\/j.ejmech.2021.113690_bib81","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.ejmech.2016.07.070","article-title":"Modulatory effects of silibinin in various cell signaling pathways against liver disorders and cancer - a comprehensive review","volume":"123","author":"Polachi","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113690_bib82","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ctrv.2017.06.003","article-title":"Targeting STAT3 with silibinin to improve cancer therapeutics","volume":"58","author":"Bosch-Barrera","year":"2017","journal-title":"Canc. Treat Rev."},{"key":"10.1016\/j.ejmech.2021.113690_bib83","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.freeradbiomed.2014.05.002","article-title":"Silybin exerts antioxidant effects and induces mitochondrial biogenesis in liver of rat with secondary biliary cirrhosis","volume":"73","author":"Serviddio","year":"2014","journal-title":"Free Radical Biol. Med."},{"key":"10.1016\/j.ejmech.2021.113690_bib84","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejmech.2015.12.041","article-title":"Silibinin derivatives as anti-prostate cancer agents: synthesis and cell-based evaluations","volume":"109","author":"Vue","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113690_bib85","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060074","article-title":"Anti-cancer efficacy of silybin derivatives -- a structure-activity relationship","volume":"8","author":"Agarwal","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.ejmech.2021.113690_bib86","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1166\/jbn.2012.1444","article-title":"In\u00a0vivo evaluation of silybin nanosuspensions targeting liver","volume":"8","author":"Wang","year":"2012","journal-title":"J.\u00a0Biomed. Nanotechnol."},{"key":"10.1016\/j.ejmech.2021.113690_bib87","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2147\/IJN.S187888","article-title":"Co-delivery doxorubicin and silybin for anti-hepatoma via enhanced oral hepatic-targeted efficiency","volume":"14","author":"Li","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejmech.2021.113690_bib88","first-page":"1940","article-title":"A\u00a0randomized trial of silymarin for the treatment of nonalcoholic steatohepatitis, clinical gastroenterology and hepatology : the official clinical practice","volume":"15","author":"Wah Kheong","year":"2017","journal-title":"J.\u00a0Am. Gastroenterol. Assoc."},{"key":"10.1016\/j.ejmech.2021.113690_bib89","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.apsb.2019.11.017","article-title":"Herbal drug discovery for the treatment of nonalcoholic fatty liver disease","volume":"10","author":"Yan","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2021.113690_bib90","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1158\/1535-7163.MCT-12-0054","article-title":"Sensitization of TRAIL-induced cell death by 20(S)-ginsenoside Rg3 via CHOP-mediated DR5 upregulation in human hepatocellular carcinoma cells","volume":"12","author":"Lee","year":"2013","journal-title":"Mol. Canc. Therapeut."},{"key":"10.1016\/j.ejmech.2021.113690_bib91","doi-asserted-by":"crossref","first-page":"8598","DOI":"10.1038\/srep08598","article-title":"Rapid preparation of rare ginsenosides by acid transformation and their structure-activity relationships against cancer cells","volume":"5","author":"Quan","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2021.113690_bib92","doi-asserted-by":"crossref","first-page":"498","DOI":"10.2174\/0929867323666160112122256","article-title":"Glycyrrhetinic acid and its derivatives: anti-cancer and cancer chemopreventive properties, mechanisms of action and structure- cytotoxic activity relationship","volume":"23","author":"Roohbakhsh","year":"2016","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113690_bib93","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20205074","article-title":"Glycyrrhizin acid and glycyrrhetinic acid modified polyethyleneimine for targeted DNA delivery to hepatocellular carcinoma","volume":"20","author":"Cao","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2021.113690_bib94","doi-asserted-by":"crossref","first-page":"6239","DOI":"10.7150\/thno.35972","article-title":"Co-delivery of glycyrrhizin and doxorubicin by alginate nanogel particles attenuates the activation of macrophage and enhances the therapeutic efficacy for hepatocellular carcinoma","volume":"9","author":"Wang","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.ejmech.2021.113690_bib95","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1124\/dmd.116.069419","article-title":"Glycyrrhizin protects against acetaminophen-induced acute liver injury via alleviating tumor necrosis factor alpha-mediated apoptosis","volume":"44","author":"Yan","year":"2016","journal-title":"Drug Metabol. Dispos.: Biol. Fate Chem."},{"key":"10.1016\/j.ejmech.2021.113690_bib96","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1478-3231.2011.02469.x","article-title":"A\u00a0glycyrrhizin-containing preparation reduces hepatic steatosis induced by hepatitis C virus protein and iron in mice","volume":"31","author":"Korenaga","year":"2011","journal-title":"Liver Int."},{"key":"10.1016\/j.ejmech.2021.113690_bib97","first-page":"2668","article-title":"Berberine prevents non-alcoholic steatohepatitis-derived hepatocellular carcinoma by inhibiting inflammation and angiogenesis in mice","volume":"11","author":"Luo","year":"2019","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.ejmech.2021.113690_bib98","first-page":"25","article-title":"Syntheses and structure-activity relationships in growth inhibition activity against human cancer cell lines of 12 substituted berberine derivatives","author":"Wang","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2021.113690_bib99","first-page":"2350","article-title":"Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer?","volume":"7","author":"Li","year":"2017","journal-title":"Am. J. Canc. Res."},{"key":"10.1016\/j.ejmech.2021.113690_bib100","doi-asserted-by":"crossref","first-page":"113261","DOI":"10.1016\/j.ejmech.2021.113261","article-title":"Discovery of 4-alkoxy-2-aryl-6,7-dimethoxyquinolines as a new class of topoisomerase I inhibitors endowed with potent in\u00a0vitro anticancer activity","volume":"215","author":"Elbadawi","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113690_bib101","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21144919","article-title":"Irinotecan-still an important player in cancer chemotherapy: a comprehensive overview","volume":"21","author":"Kciuk","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2021.113690_bib102","doi-asserted-by":"crossref","first-page":"5535","DOI":"10.1016\/j.bmc.2010.06.040","article-title":"The structure-activity relationships of A-ring-substituted aromathecin topoisomerase I inhibitors strongly support a camptothecin-like binding mode","volume":"18","author":"Cinelli","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113690_bib103","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/hep.28621","article-title":"Patient-derived mouse xenografts from pediatric liver cancer predict tumor recurrence and advise clinical management","volume":"64","author":"Nicolle","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2021.113690_bib104","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.molimm.2016.12.001","article-title":"Arsenic trioxide is an immune adjuvant in liver cancer treatment","volume":"81","author":"Wang","year":"2017","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.ejmech.2021.113690_bib105","first-page":"321","article-title":"Arsenic trioxide reverses the chemoresistance in hepatocellular carcinoma: a targeted intervention of 14-3-3eta\/NF-kappaB feedback loop","volume":"37","author":"Qiu","year":"2018","journal-title":"J.\u00a0Exp. Clin. Canc. Res. : CR (Clim. Res.)"},{"key":"10.1016\/j.ejmech.2021.113690_bib106","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1039\/C4SC03540B","article-title":"Identification of a fluorometabolite from Streptomyces sp. MA37: (2R3S4S)-5-fluoro-2,3,4-trihydroxypentanoic acid","volume":"6","author":"Ma","year":"2015","journal-title":"Chem. Sci."},{"key":"10.1016\/j.ejmech.2021.113690_bib107","doi-asserted-by":"crossref","first-page":"27047","DOI":"10.1039\/C6RA00100A","article-title":"Biological fluorination from the sea: discovery of a SAM-dependent nucleophilic fluorinating enzyme from the marine-derived bacterium Streptomyces xinghaiensis NRRL B24674","volume":"6","author":"Ma","year":"2016","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2021.113690_bib108","doi-asserted-by":"crossref","first-page":"4769","DOI":"10.1016\/j.ejmech.2011.07.057","article-title":"Natural products: an evolving role in future drug discovery","volume":"46","author":"Mishra","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113690_bib109","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1021\/acs.chemrestox.6b00413","article-title":"Dietary phytochemicals and cancer chemoprevention: a perspective on oxidative stress, inflammation, and epigenetics","volume":"29","author":"Li","year":"2016","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.ejmech.2021.113690_bib110","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1021\/acs.jafc.6b04797","article-title":"Curcumin attenuates N-Nitrosodiethylamine-Induced liver injury in mice by utilizing the method of metabonomics","volume":"65","author":"Qiu","year":"2017","journal-title":"J.\u00a0Agric. Food Chem."},{"key":"10.1016\/j.ejmech.2021.113690_bib111","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/mc.22100","article-title":"Genistein inhibits hepatocellular carcinoma cell migration by reversing the epithelial-mesenchymal transition: partial mediation by the transcription factor NFAT1","volume":"54","author":"Dai","year":"2015","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.ejmech.2021.113690_bib112","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2015.271","article-title":"Autophagy-induced RelB\/p52 activation mediates tumour-associated macrophage repolarisation and suppression of hepatocellular carcinoma by natural compound baicalin","volume":"6","author":"Tan","year":"2015","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejmech.2021.113690_bib113","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.taap.2011.07.008","article-title":"Baicalein inhibits the migration and invasive properties of human hepatoma cells","volume":"255","author":"Chiu","year":"2011","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.ejmech.2021.113690_bib114","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3390\/ijms17040577","article-title":"Up-regulation of PAI-1 and down-regulation of uPA are involved in suppression of invasiveness and motility of hepatocellular carcinoma cells by a natural compound berberine","volume":"17","author":"Wang","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2021.113690_bib115","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ijbiomac.2013.11.034","article-title":"Huaier polysaccharides suppresses hepatocarcinoma MHCC97-H cell metastasis via inactivation of EMT and AEG-1 pathway","volume":"64","author":"Zheng","year":"2014","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ejmech.2021.113690_bib116","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.cbi.2016.06.026","article-title":"Utilization of metabonomics to identify serum biomarkers in murine H22 hepatocarcinoma and deduce antitumor mechanism of Rhizoma Paridis saponins","volume":"256","author":"Qiu","year":"2016","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.ejmech.2021.113690_bib117","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jpba.2017.08.019","article-title":"Development of a LC-MS\/MS method to investigate the interference of pharmacokinetics of the main constituents in Saxifraga stolonifera: involvement of drug metabolism enzymes","volume":"148","author":"Wang","year":"2017","journal-title":"J.\u00a0Pharmaceut. Biomed. Anal."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421005390?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421005390?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:28:56Z","timestamp":1759328936000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523421005390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":117,"alternative-id":["S0223523421005390"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.113690","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment for liver cancer: From sorafenib to natural products","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.113690","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113690"}}